3rd Quarter - Report

EMERGENT BIOSOLUTIONS INC. for EMERGENT BIOSOLUTIONS INC

Firm
Client
Income
—
Expenses
$680,000
Expense method
C: businesses, Internal Revenue Code section 162(e)

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
3rd Quarter - Report Oct 16, 2009 $590,000 Replaced
3rd Quarter - Report (this page) Jan 20, 2010 $680,000 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Homeland Security HOM

P.L. 115-5 - American Recovery & Reinvestment Act of 2009 - implementation of provisions relating to biodefense funding; H.R.3288 - Consolidated Appropriations Act, 2010, Division D - Department of Labor, Health & Human Services and Education Appropriations Act of 2010 - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. H.R. 2892 and S. 1298 - Department of Homeland Security Appropriations Act, 2010 - all provisions relating to the development, acquistion and stockpiling of biodefense vaccines; S. 1649 - WMD Prevention and Prepardeness Act of 2009 - all provisions relating to the development , acquistion and stockpiling of biodefense vaccines; Implementation of the Biomedical Advanced Research & Development Authority (BARDA) & Project BioShield relationg to stockpiling of biodefense vaccines.

LobbyistCovered position, as disclosed
ASHLEY BRATICH —
CHRIS FRECH —
ALLEN SHOFE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 1298 (111th), H.R. 3288 (111th), H.R. 2892 (111th), S. 1649 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.